oxymetazoline has been researched along with Acne Rosacea in 32 studies
Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 2298 participants were included, and the improvement rate of two-grade Clinician Erythema Assessment score (CEA) and Subject Self-Assessment for rosacea facial redness score (SSA) in Oxymetazoline group was 38% (95%CI 28-48) and 25% (95%CI 22-27), respectively, at the 4th week of the dosing." | 9.41 | Benefits and safety of Oxymetazoline cream 1% on rosacea-associated erythema: A systematic review and analysis of clinical evidence. ( Yin, D; Yuan, X, 2023) |
| "18) -hours SSA success rate after oxymetazoline treatment for rosacea is significantly higher than that of vehicle." | 9.41 | Efficacy and safety of oxymetazoline for the treatment of rosacea: A meta-analysis. ( Cao, Y; Fu, H; Li, Y; Liu, F; Luo, H; Tao, M; Wang, H; Zhou, Q, 2023) |
| "We evaluated if oxymetazoline therapy combined with 595-nm pulsed dye laser (PDL) will be more beneficial than topical oxymetazoline alone for the improvement of erythematotelangiectatic rosacea." | 9.41 | A Randomized Controlled Pilot Study: Combined 595-nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea. ( Friedman, PM; Munavalli, GS; Sodha, P; Suggs, A, 2021) |
| "Assessment of study photographs, with comparison to baseline, confirmed significant erythema reduction with oxymetazoline on the first day of application." | 9.30 | Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV stu ( Alvandi, N; Baldwin, HE; Del Rosso, JQ; Eichenfield, LF; Harper, J; Hebert, AA; Kaoukhov, A; Kircik, LH; Stein-Gold, L; Tan, JKL; Webster, GF, 2019) |
| "A ≥1-grade improvement in persistent erythema achieved after the first dose of once-daily topical oxymetazoline demonstrated clinically meaningful improvement from the beginning of therapy." | 9.27 | Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0. ( Ahluwalia, G; Alvandi, N; Berk, DR; Dhawan, SS; Dover, JS; Goldberg, DJ; Luo, L; Tanghetti, EA, 2018) |
| "These findings support the use of oxymetazoline for the treatment of persistent facial erythema associated with rosacea." | 9.27 | Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea. ( Ahluwalia, G; Attar, M; DuBois, J; Kuang, AW, 2018) |
| "This phase 2 study evaluated the optimal oxymetazoline dosing regimen in patients with moderate to severe persistent facial erythema of rosacea." | 9.27 | Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea. ( Ahluwalia, G; Berk, DR; Dover, JS; DuBois, J; Jones, TM; Weiss, RA, 2018) |
| "This long-term study demonstrated sustained safety, tolerability, and efficacy of oxymetazoline for moderate-to-severe persistent erythema of rosacea." | 9.27 | Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. ( Ahluwalia, G; Alvandi, N; Baumann, L; Berk, DR; Draelos, ZD; Gold, MH; Grekin, SK; Kempers, SE; Robinson, DM; Weiss, RA; Weng, E, 2018) |
| " Patients with moderate to severe persistent erythema of rosacea were randomized to receive oxymetazoline cream 1." | 9.27 | Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials ( Ahluwalia, G; Alvandi, N; Baumann, L; Berk, D; Draelos, ZD; DuBois, J; Goldberg, D; Kaufman, J; Kircik, L; Lain, E; Stein-Gold, L; Tanghetti, E; Weng, E; Werschler, P, 2018) |
| "Literature searches of MEDLINE (1975 to September 2017), International Pharmaceutical Abstracts (1975 to September 2017), and Cochrane Database (publications through September 2017) using the terms rosacea, persistent redness, α -agonist, and oxymetazoline." | 8.98 | Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea. ( Erramouspe, J; Hoover, RM, 2018) |
| "The objectives of this study were to evaluate the safety, tolerability, and efficacy of oxymetazoline hydrochloride cream, 1% (oxymetazoline) when used as an adjunctive treatment with energy-based therapy for patients with moderate to severe facial erythema associated with rosacea." | 8.02 | Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study. ( Alvandi, N; Bai, Z; Dover, JS; Geronemus, RG; Goldberg, DJ; Shanler, SD; Tanghetti, EA, 2021) |
| "When applied topically, oxymetazoline and brimonidine reduce the persistent facial erythema of rosacea; this effect is mediated by cutaneous vasoconstriction induced by postsynaptic activation of α-adrenoceptors." | 7.88 | Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors. ( Gil, D; Hsia, E; Tian, M, 2018) |
| " Safety assessments included treatment-emergent adverse events (TEAEs) and posttreatment worsening of erythema (composite CEA/SSA increase of 1-grade severity from baseline; rebound effect)." | 6.87 | Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial. ( Ahluwalia, G; Berk, DR; Cook-Bolden, FE; Draelos, ZD; DuBois, J; Grande, K; Kircik, LH; Weng, E; Werschler, P, 2018) |
| " Safety assessments included treatment-emergent adverse events (TEAEs) and dermal tolerability." | 6.87 | Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial. ( Ahluwalia, G; Baumann, L; Berk, DR; Goldberg, DJ; Kaufman, J; Lain, E; Stein Gold, L; Tanghetti, EA; Weng, E, 2018) |
| "Rosacea is a chronic skin condition characterized by transient and persistent erythema of the central face." | 6.55 | Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. ( Feldman, SR; Patel, NU; Shukla, S; Zaki, J, 2017) |
| "Oxymetazoline 1." | 5.56 | Treatment of Erythematotelangiectatic Rosacea With Pulsed-Dye Laser and Oxymetazoline 1.0% Cream: A Retrospective Study. ( Friedman, PM; Macri, A; Munavalli, G; Richmond, H; Suggs, AK, 2020) |
| "A total of 2298 participants were included, and the improvement rate of two-grade Clinician Erythema Assessment score (CEA) and Subject Self-Assessment for rosacea facial redness score (SSA) in Oxymetazoline group was 38% (95%CI 28-48) and 25% (95%CI 22-27), respectively, at the 4th week of the dosing." | 5.41 | Benefits and safety of Oxymetazoline cream 1% on rosacea-associated erythema: A systematic review and analysis of clinical evidence. ( Yin, D; Yuan, X, 2023) |
| "18) -hours SSA success rate after oxymetazoline treatment for rosacea is significantly higher than that of vehicle." | 5.41 | Efficacy and safety of oxymetazoline for the treatment of rosacea: A meta-analysis. ( Cao, Y; Fu, H; Li, Y; Liu, F; Luo, H; Tao, M; Wang, H; Zhou, Q, 2023) |
| "We evaluated if oxymetazoline therapy combined with 595-nm pulsed dye laser (PDL) will be more beneficial than topical oxymetazoline alone for the improvement of erythematotelangiectatic rosacea." | 5.41 | A Randomized Controlled Pilot Study: Combined 595-nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea. ( Friedman, PM; Munavalli, GS; Sodha, P; Suggs, A, 2021) |
| "Assessment of study photographs, with comparison to baseline, confirmed significant erythema reduction with oxymetazoline on the first day of application." | 5.30 | Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV stu ( Alvandi, N; Baldwin, HE; Del Rosso, JQ; Eichenfield, LF; Harper, J; Hebert, AA; Kaoukhov, A; Kircik, LH; Stein-Gold, L; Tan, JKL; Webster, GF, 2019) |
| "A ≥1-grade improvement in persistent erythema achieved after the first dose of once-daily topical oxymetazoline demonstrated clinically meaningful improvement from the beginning of therapy." | 5.27 | Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0. ( Ahluwalia, G; Alvandi, N; Berk, DR; Dhawan, SS; Dover, JS; Goldberg, DJ; Luo, L; Tanghetti, EA, 2018) |
| "These findings support the use of oxymetazoline for the treatment of persistent facial erythema associated with rosacea." | 5.27 | Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea. ( Ahluwalia, G; Attar, M; DuBois, J; Kuang, AW, 2018) |
| "This long-term study demonstrated sustained safety, tolerability, and efficacy of oxymetazoline for moderate-to-severe persistent erythema of rosacea." | 5.27 | Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. ( Ahluwalia, G; Alvandi, N; Baumann, L; Berk, DR; Draelos, ZD; Gold, MH; Grekin, SK; Kempers, SE; Robinson, DM; Weiss, RA; Weng, E, 2018) |
| " Patients with moderate to severe persistent erythema of rosacea were randomized to receive oxymetazoline cream 1." | 5.27 | Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials ( Ahluwalia, G; Alvandi, N; Baumann, L; Berk, D; Draelos, ZD; DuBois, J; Goldberg, D; Kaufman, J; Kircik, L; Lain, E; Stein-Gold, L; Tanghetti, E; Weng, E; Werschler, P, 2018) |
| "This phase 2 study evaluated the optimal oxymetazoline dosing regimen in patients with moderate to severe persistent facial erythema of rosacea." | 5.27 | Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea. ( Ahluwalia, G; Berk, DR; Dover, JS; DuBois, J; Jones, TM; Weiss, RA, 2018) |
| "Topical oxymetazoline and brimonidine are the only medications approved for treating persistent facial erythema of rosacea." | 5.12 | Difference in vasoconstrictors: oxymetazoline vs. brimonidine. ( Cline, A; Feldman, SR; Okwundu, N, 2021) |
| "Literature searches of MEDLINE (1975 to September 2017), International Pharmaceutical Abstracts (1975 to September 2017), and Cochrane Database (publications through September 2017) using the terms rosacea, persistent redness, α -agonist, and oxymetazoline." | 4.98 | Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea. ( Erramouspe, J; Hoover, RM, 2018) |
| "The objectives of this study were to evaluate the safety, tolerability, and efficacy of oxymetazoline hydrochloride cream, 1% (oxymetazoline) when used as an adjunctive treatment with energy-based therapy for patients with moderate to severe facial erythema associated with rosacea." | 4.02 | Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study. ( Alvandi, N; Bai, Z; Dover, JS; Geronemus, RG; Goldberg, DJ; Shanler, SD; Tanghetti, EA, 2021) |
| "When applied topically, oxymetazoline and brimonidine reduce the persistent facial erythema of rosacea; this effect is mediated by cutaneous vasoconstriction induced by postsynaptic activation of α-adrenoceptors." | 3.88 | Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors. ( Gil, D; Hsia, E; Tian, M, 2018) |
| " Safety assessments included treatment-emergent adverse events (TEAEs) and dermal tolerability." | 2.87 | Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial. ( Ahluwalia, G; Baumann, L; Berk, DR; Goldberg, DJ; Kaufman, J; Lain, E; Stein Gold, L; Tanghetti, EA; Weng, E, 2018) |
| " Safety assessments included treatment-emergent adverse events (TEAEs) and posttreatment worsening of erythema (composite CEA/SSA increase of 1-grade severity from baseline; rebound effect)." | 2.87 | Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial. ( Ahluwalia, G; Berk, DR; Cook-Bolden, FE; Draelos, ZD; DuBois, J; Grande, K; Kircik, LH; Weng, E; Werschler, P, 2018) |
| "Rosacea is a chronic cutaneous disorder affecting primarily the face, characterized by erythema, transient or persistent, telangiectasia, and inflammatory lesions including papulo-pustules and swelling." | 2.82 | Rosacea management: A comprehensive review. ( Galadari, H; Goldust, M; Goren, A; Grabbe, S; Kassir, M; Kroumpouzos, G; Sharma, A, 2022) |
| "Rosacea is a common chronic facial dermatosis." | 2.61 | Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. ( Arents, BWM; Carter, B; Charland, L; Fedorowicz, Z; Tan, J; van der Linden, MMD; van Zuuren, EJ, 2019) |
| "Rosacea is a chronic skin condition characterized by transient and persistent erythema of the central face." | 2.55 | Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. ( Feldman, SR; Patel, NU; Shukla, S; Zaki, J, 2017) |
| "Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans." | 2.52 | New and Emerging Treatments for Rosacea. ( Draelos, ZD; Gold, LM, 2015) |
| "Rosacea is a chronic inflammatory skin condition that negatively impacts patients' quality of life." | 2.50 | Rosacea: new and emerging treatments. ( Feldman, SR; Moustafa, FA; Sandoval, LF, 2014) |
| "Oxymetazoline (OXZ) is a synthetic, highly selective agonist for alpha 1A-adrenoceptor." | 1.72 | A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema. ( Agamia, N; El-Ariny, A; El-Nagdy, S, 2022) |
| "Oxymetazoline 1." | 1.56 | Treatment of Erythematotelangiectatic Rosacea With Pulsed-Dye Laser and Oxymetazoline 1.0% Cream: A Retrospective Study. ( Friedman, PM; Macri, A; Munavalli, G; Richmond, H; Suggs, AK, 2020) |
| "Rosacea is a common inflammatory skin condition that impacts a large portion of fair-skinned populations." | 1.48 | Fifteen Minute Test May Save 15% or More on Rosacea Treatment. ( Cervantes, J; Darwin, E; Lev-Tov, H, 2018) |
| "Rosacea is a common chronic skin disorder that has significant impact on the self-esteem and quality of life of affected individuals." | 1.38 | Rosacea: update on management and emerging therapies. ( Fallen, RS; Gooderham, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.13) | 29.6817 |
| 2010's | 23 (71.88) | 24.3611 |
| 2020's | 8 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agamia, N | 1 |
| El-Nagdy, S | 1 |
| El-Ariny, A | 1 |
| Sharma, A | 1 |
| Kroumpouzos, G | 1 |
| Kassir, M | 1 |
| Galadari, H | 1 |
| Goren, A | 1 |
| Grabbe, S | 1 |
| Goldust, M | 1 |
| Yuan, X | 1 |
| Yin, D | 1 |
| Liu, F | 1 |
| Zhou, Q | 1 |
| Wang, H | 1 |
| Fu, H | 1 |
| Li, Y | 1 |
| Tao, M | 1 |
| Luo, H | 1 |
| Cao, Y | 1 |
| Suggs, AK | 1 |
| Macri, A | 1 |
| Richmond, H | 1 |
| Munavalli, G | 1 |
| Friedman, PM | 2 |
| Tanghetti, EA | 3 |
| Goldberg, DJ | 3 |
| Dover, JS | 3 |
| Geronemus, RG | 1 |
| Bai, Z | 1 |
| Alvandi, N | 6 |
| Shanler, SD | 2 |
| Sodha, P | 1 |
| Suggs, A | 1 |
| Munavalli, GS | 1 |
| Patel, NU | 1 |
| Shukla, S | 1 |
| Zaki, J | 1 |
| Feldman, SR | 4 |
| Hoover, RM | 1 |
| Erramouspe, J | 1 |
| Kircik, LH | 2 |
| DuBois, J | 4 |
| Draelos, ZD | 4 |
| Werschler, P | 2 |
| Grande, K | 1 |
| Cook-Bolden, FE | 1 |
| Weng, E | 4 |
| Berk, DR | 6 |
| Ahluwalia, G | 8 |
| Gold, MH | 2 |
| Weiss, RA | 2 |
| Baumann, L | 3 |
| Grekin, SK | 1 |
| Robinson, DM | 2 |
| Kempers, SE | 1 |
| Kuang, AW | 1 |
| Attar, M | 1 |
| Cline, A | 2 |
| McGregor, SP | 1 |
| Stein Gold, L | 1 |
| Lain, E | 2 |
| Kaufman, J | 2 |
| Jones, TM | 1 |
| Hsia, E | 1 |
| Tian, M | 1 |
| Gil, D | 1 |
| Lebwohl, M | 1 |
| Biesman, BS | 1 |
| Luo, L | 2 |
| Dhawan, SS | 1 |
| Darwin, E | 1 |
| Cervantes, J | 1 |
| Lev-Tov, H | 1 |
| Garcia, C | 1 |
| Birch, M | 1 |
| Eichenfield, LF | 1 |
| Del Rosso, JQ | 2 |
| Tan, JKL | 1 |
| Hebert, AA | 1 |
| Webster, GF | 1 |
| Harper, J | 1 |
| Baldwin, HE | 1 |
| Stein-Gold, L | 2 |
| Kaoukhov, A | 1 |
| Kircik, L | 1 |
| Goldberg, D | 1 |
| Tanghetti, E | 2 |
| Berk, D | 1 |
| van Zuuren, EJ | 1 |
| Fedorowicz, Z | 1 |
| Tan, J | 1 |
| van der Linden, MMD | 1 |
| Arents, BWM | 1 |
| Carter, B | 1 |
| Charland, L | 1 |
| Okwundu, N | 1 |
| Fowler, J | 1 |
| Moustafa, FA | 1 |
| Sandoval, LF | 1 |
| Gold, LM | 1 |
| Fallen, RS | 1 |
| Gooderham, M | 1 |
| Ondo, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study to Evaluate Vbeam® Prima Pulsed Dye Laser (PDL) Treatment and RHOFADE® (Oxymetazoline HCL, 1% Cream) for Erythematotelangiectatic Rosacea[NCT04153188] | Phase 4 | 34 participants (Actual) | Interventional | 2019-01-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CEA was graded by the investigator according to 5-point scale (0=Clear to 4=Severe) for each patient at the 6-month post-baseline visits. A higher score indicates worse outcome. The outcomes presented here are the mean CEA calculated for the 6-month post-baseline visit of each arm. (NCT04153188)
Timeframe: 6-month post-baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Pulsed Dye Laser & Oxymetazoline HCL 1% Cream | 1.6 |
| Oxymetazoline HCL 1% Cream | 2.4 |
A standard 10-centimeter visual analog scale from 0=No pain to 10=worst pain was used by subjects to report pain level associated with PDL treatment. A higher score indicates greater pain/discomfort with treatment. Mean of all pain associated scores obtained for all PDL treatments was calculated. (NCT04153188)
Timeframe: 1-, 2- and 3-month post-baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Pulsed Dye Laser & Oxymetazoline HCL 1% Cream | 4.5 |
Subject satisfaction is graded according to 5-point scale (0=Very Satisfied to 4=Very Dissatisfied). Lower score indicates higher satisfaction. A score of 0 or 1 indicates satisfaction with treatment outcome. The measurements reflect the percentage of subjects that were satisfied (graded 0 or 1) at the 6-month post-baseline visit (NCT04153188)
Timeframe: 6-month post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Pulsed Dye Laser & Oxymetazoline HCL 1% Cream | 12 |
| Oxymetazoline HCL 1% Cream | 7 |
Clinical Erythema Assessment (CEA) scores at the 1- ,2- and 3-month post-baseline visits were assessed for each patient by the investigator. CEA scores were graded according to 5-point scale (0=Clear to 4=Severe). A higher score indicates worse outcome. The outcomes presented here are the mean CEA calculated for each visit. (NCT04153188)
Timeframe: 1- ,2- and 3-Month Post-Baseline Visits
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Clinical Erythema Assessment (CEA) At 1-Month Post-Baseline | Clinical Erythema Assessment (CEA) At 2-Month Post-Baseline | Clinical Erythema Assessment (CEA) At 3-Month Post-Baseline | |
| Oxymetazoline HCL 1% Cream | 2.6 | 2.0 | 2.3 |
| Pulsed Dye Laser & Oxymetazoline HCL 1% Cream | 2.6 | 2.5 | 2.0 |
Investigator measurement of Global Aesthetic Improvement (GAI) with treatment. GAI is graded according to 5-point scale (0=Excellent improvement to 4=No change). A higher score indicates a worse outcome. The outcomes presented here are the mean GAI calculated for each visit. (NCT04153188)
Timeframe: 1-, 2-, 3- and 6-month post-baseline
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Mean GAI Grade at 1-Months Post-Baseline Visit | Mean GAI Grade at 2-Months Post-Baseline Visit | Mean GAI Grade at 3-Months Post-Baseline Visit | Mean GAI Grade at 6-Months Post-Baseline Visit | |
| Oxymetazoline HCL 1% Cream | 2.7 | 1.4 | 2.5 | 2.5 |
| Pulsed Dye Laser & Oxymetazoline HCL 1% Cream | 2.5 | 2.3 | 1.7 | 1.2 |
Subject measurement of Global Aesthetic Improvement (GAI) with treatment. GAI is graded according to 5-point scale (0=Excellent improvement to 4=No change). A higher score indicates a worse outcome. The outcomes presented here are the mean GAI calculated for each visit. (NCT04153188)
Timeframe: 1-, 2-, 3- and 6-month post-baseline
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Mean GAI Grade at 1-Months Post-Baseline Visit | Mean GAI Grade at 2-Months Post-Baseline Visit | Mean GAI Grade at 3-Months Post-Baseline Visit | Mean GAI Grade at 6-Months Post-Baseline Visit | |
| Oxymetazoline HCL 1% Cream | 2.9 | 2.4 | 2.6 | 2.1 |
| Pulsed Dye Laser & Oxymetazoline HCL 1% Cream | 2.6 | 1.9 | 1.2 | 0.7 |
Investigator assessment of improvement in vessel size with treatment. Improvement in vessel size is graded according to 4-point scale (0=76-100% improvement (excellent) to 4=No response). A higher score indicates a worse outcome. Mean score was calculated for each visit. (NCT04153188)
Timeframe: 1-, 2-, 3- and 6-month post-baseline
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Mean Vessel Size Improvement Grade at 1-Month Post-Baseline Visit | Mean Vessel Size Improvement Grade at 2-Month Post-Baseline Visit | Mean Vessel Size Improvement Grade at 3-Month Post-Baseline Visit | Mean Vessel Size Improvement Grade at 6-Month Post-Baseline Visit | |
| Oxymetazoline HCL 1% Cream | 3.2 | 2.7 | 3.1 | 3.1 |
| Pulsed Dye Laser & Oxymetazoline HCL 1% Cream | 3.4 | 2.4 | 1.8 | 1.6 |
Subject Self-Assessment (SSA) at the 1- ,2-, 3- and 6-month post-baseline visits were graded according to 5-point scale (0=Clear of unwanted redness to 4=Completely unacceptable redness) at each visit. A higher score indicates worse outcome. (NCT04153188)
Timeframe: 1-, 2-, 3- and 6-months post-baseline
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Subject Self-Assessment (SSA) At the 1-Month Post Baseline | Subject Self-Assessment (SSA) At the 2-Month Post Baseline | Subject Self-Assessment (SSA) At the 3-Month Post Baseline | Subject Self-Assessment (SSA) At the 6-Month Post Baseline | |
| Oxymetazoline HCL 1% Cream | 3.0 | 2.3 | 2.3 | 2.2 |
| Pulsed Dye Laser & Oxymetazoline HCL 1% Cream | 3.3 | 2.7 | 2.1 | 1.4 |
10 reviews available for oxymetazoline and Acne Rosacea
| Article | Year |
|---|---|
Rosacea management: A comprehensive review.
Topics: Anti-Bacterial Agents; Dermatologic Agents; Erythema; Female; Humans; Male; Oxymetazoline; Rosacea; | 2022 |
Benefits and safety of Oxymetazoline cream 1% on rosacea-associated erythema: A systematic review and analysis of clinical evidence.
Topics: Emollients; Erythema; Humans; Oxymetazoline; Rosacea; Skin Cream; Treatment Outcome | 2023 |
Efficacy and safety of oxymetazoline for the treatment of rosacea: A meta-analysis.
Topics: Dermatitis; Humans; Oxymetazoline; Randomized Controlled Trials as Topic; Rosacea; Skin Cream; Treat | 2023 |
Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
Topics: Administration, Cutaneous; Adrenergic alpha-Agonists; Dermatologic Agents; Erythema; Humans; Oxymeta | 2017 |
Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Drug Interactions; Erythema; Humans; Oxymetazoli | 2018 |
Medical Management of Facial Redness in Rosacea.
Topics: Administration, Cutaneous; Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; | 2018 |
Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Brimonidine Tartrate; Combin | 2019 |
Difference in vasoconstrictors: oxymetazoline vs. brimonidine.
Topics: Administration, Topical; Brimonidine Tartrate; Clinical Trials as Topic; Dermatitis; Erythema; Human | 2021 |
Rosacea: new and emerging treatments.
Topics: Administration, Cutaneous; Brimonidine Tartrate; Dermatologic Agents; Drug Design; Humans; Ivermecti | 2014 |
New and Emerging Treatments for Rosacea.
Topics: Administration, Topical; Brimonidine Tartrate; Clinical Trials, Phase III as Topic; Dermatologic Age | 2015 |
10 trials available for oxymetazoline and Acne Rosacea
| Article | Year |
|---|---|
A Randomized Controlled Pilot Study: Combined 595-nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea.
Topics: Humans; Lasers, Dye; Oxymetazoline; Pilot Projects; Prospective Studies; Rosacea; Skin Cream; Treatm | 2021 |
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Dermatitis; Double-Blind Method; Erythema | 2018 |
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration | 2018 |
Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Aged; Dose-Response Relationship, Drug; D | 2018 |
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Erythema; Face; Female; Humans; Mal | 2018 |
Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea.
Topics: Adult; Aged; Erythema; Face; Female; Humans; Male; Middle Aged; Oxymetazoline; Rosacea; Skin Cream; | 2018 |
Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Erythema; Facial Dermatoses; Humans; Oxymetazoline; Ro | 2018 |
Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Compo | 2018 |
Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV stu
Topics: Erythema; Face; Female; Humans; Male; Middle Aged; Oxymetazoline; Patient Reported Outcome Measures; | 2019 |
Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials
Topics: Adult; Erythema; Female; Humans; Male; Oxymetazoline; Rosacea; Self-Assessment; Severity of Illness | 2018 |
12 other studies available for oxymetazoline and Acne Rosacea
| Article | Year |
|---|---|
A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema.
Topics: Acne Vulgaris; Administration, Topical; Brimonidine Tartrate; Drug Therapy, Combination; Erythema; H | 2022 |
Treatment of Erythematotelangiectatic Rosacea With Pulsed-Dye Laser and Oxymetazoline 1.0% Cream: A Retrospective Study.
Topics: Adrenergic alpha-Agonists; Adult; Combined Modality Therapy; Female; Humans; Lasers, Dye; Low-Level | 2020 |
Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study.
Topics: Erythema; Female; Humans; Male; Middle Aged; Oxymetazoline; Rosacea; Skin Cream; Treatment Outcome | 2021 |
Oxymetazoline cream (Rhofade) for rosacea.
Topics: Administration, Cutaneous; Adrenergic alpha-1 Receptor Agonists; Dermatologic Agents; Humans; Oxymet | 2017 |
Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Calcium; Dis | 2018 |
Fifteen Minute Test May Save 15% or More on Rosacea Treatment.
Topics: Adrenergic alpha-Agonists; Dermatologic Agents; Humans; Oxymetazoline; Rosacea; Skin Tests; Time Fac | 2018 |
Oxymetazoline Hydrochloride 1% Cream (Rhofade) for Persistent Facial Erythema Associated with Rosacea.
Topics: Administration, Cutaneous; Adrenergic alpha-Agonists; Erythema; Humans; Oxymetazoline; Rosacea; Skin | 2018 |
The importance of good photography in clinical trials and in the clinic.
Topics: Ambulatory Care Facilities; Erythema; Humans; Oxymetazoline; Photography; Rosacea | 2019 |
Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy?
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Erythema; Hum | 2013 |
New agents for the treatment of erythematotelangiectatic rosacea.
Topics: Brimonidine Tartrate; Clinical Trials as Topic; Dermatologic Agents; Gels; Humans; Oxymetazoline; Qu | 2014 |
Rosacea: update on management and emerging therapies.
Topics: Administration, Cutaneous; Adrenergic Agents; Anti-Infective Agents; Antiparasitic Agents; Brimonidi | 2012 |
Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Aged; Erythema; Female; Flushing; H | 2007 |